List view / Grid view
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
30 September 2015 | By Victoria White
BLU-554, an exquisitely selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), is currently being evaluated in a Phase 1 clinical trial in patients with advanced hepatocellular carcinoma...
10 September 2015 | By Victoria White
BLU-285 is a potent and highly selective inhibitor of the KIT D816V mutant, the primary driver of disease in more than 94% of systemic mastocytosis patients...
23 June 2015 | By Victoria White
Blueprint Medicines has announced the first preclinical data for its drug candidate BLU6864, a RET-specific kinase inhibitor.
24 April 2015 | By Victoria White
New preclinical data demonstrates that BLU-554 has significant anti-tumour activity in models of HCC that are dependent on FGFR4 signalling...
20 April 2015 | By Victoria White
New preclinical data demonstrates that BLU-285 has significant anti-tumour activity in treatment-resistant models of gastrointestinal stromal tumours (GIST)...
